Irhan Ibrahim Abu Hashim

Irhan Ibrahim Abu Hashim

Auto-generated profile, based on publicly available information

Irhan Ibrahim Abu Hashim

Department of Pharmaceutical Sciences and Pharmaceutics, Faculty of Pharmacy, Applied Science Private University. Amman, Jordan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
MEMona Ebrahim Elmoghayer
Mona Ebrahim Elmoghayer
NSNoha Saleh
Noha Saleh
IHIrhan Ibrahim Abu Hashim
Irhan Ibrahim Abu Hashim
Hesperidin (Hsd), a bioactive phytomedicine, experienced an antidiabetic activity versus both Type 1 and Type 2 Diabetes mellitus. However, its intrinsic poor solubility and bioavailability is a key challenging obstacle reflecting its oral delivery. From such perspective, the purpose of the current study was to prepare and evaluate Hsd-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles (Hsd/CD/CS NPs) for improving the hypoglycemic activity of the orally administered Hsd. Hsd was first complexed with sulfobutylether-β-cyclodextrin (SBE-β-CD) and the complex (CX) was found to be formed with percent complexation efficiency and percent process efficiency of 50.53 ± 1.46 and 84.52 ± 3.16%, respectively. Also, solid state characterization of the complex ensured the inclusion of Hsd inside the cavity of SBE-β-CD. Then, Hsd/CD/CS NPs were prepared using the ionic gelation technique. The prepared NPs were fully characterized to select the most promising one (F1) with a homogenous particle size of 455.7 ± 9.04 nm, a positive zeta potential of + 32.28 ± 1.12 mV, and an entrapment efficiency of 77.46 ± 0.39%. The optimal formula (F1) was subjected to further investigation of in vitro release, ex vivo intestinal permeation, stability, cytotoxicity, and in vivo hypoglycemic activity. The results of the release and permeation studies of F1 manifested a modulated pattern between Hsd and CX. The preferential stability of F1 was observed at 4 ± 1 °C. Also, the biocompatibility of F1 with oral epithelial cell line (OEC) was retained up to a concentration of 100 µg/mL. After oral administration of F1, a noteworthy synergistic hypoglycemic effect was recorded with decreased blood glucose level until the end of the experiment. In conclusion, Hsd/CD/CS NPs could be regarded as a hopeful oral delivery system of Hsd with enhanced antidiabetic activity. Graphical Abstract

7 January 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
IHIbrahim Hashim
Ibrahim Hashim
AAAlia Kh. Alsuwais
Alia Kh. Alsuwais
AAAlaa ABU Alhaija
Alaa ABU Alhaija
AAAhmad Aljaberi
Ahmad Aljaberi
Objective: Polyethylene Oxide (PEO) is an amphiphilic polymer available in various grades, allowing manipulation of drug release rates. This work hypothesized the attempt to combine Hot-Melt Extrusion (HME) and Design of Experiments (DoE) with mixtures of various PEO grades to efficiently produce a dosage form with tailored drug release. Methods: MODDE software recommended sixteen runs. A D-optimal mixture design evaluated the effects of gliclazide, PEO 303, and PEO 205 on the release profile of extrudates containing, as well fixed amounts of Polyethylene Glycol (PEG) 8000 and Colloidal Silicon Dioxide (CSD). The formulations were extruded at a screw speed of 20 rpm using a vertical lab-scale single screw with four heating zones set at 85, 90, 90, and 95 °C. The most discriminative dissolution method was used to generate release profiles of extrudate containing 30 mg of the drug. Factors affecting the drug release rate at 1, 3, 4, and 6 h were identified and modeled. Results: The goodness of fit (R2) and prediction (Q2) for release responses were 0.969 and 0.830 at 1 h, 0.983 and 0.760 at 3 h, 0.987 and 0.687 at 4 h, and 0.947 and 0.786 at 6 h, respectively. The optimal design space for PEO 303 as a release-retarding polymer and PEO 205 as a release modifier at each gliclazide level (10–30%) was successfully constructed by Response Surface Modeling (RSM). Conclusion: This work produced an extended-release profile of gliclazide that mimics the innovator by leveraging HME and DoE.